Recent Updates
Recently added Catalysts
QGEN Positive Sentiment

QIAGEN Shareholders Overwhelmingly Approve Jonathan M. Pratt as Managing Director

Friday, November 6, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: QIAGEN N.V. announced that shareholders approved Jonathan M. Pratt as Managing Director during an Extraordinary General Meeting. Pratt, who became CEO on September 1, 2026, will join CFO Roland Sackers on the Managing Board. This decision reflects strong support from shareholders for the new leadership.

Market Sentiment Analysis

POSITIVE FACTORS

  • Shareholders approved Jonathan M. Pratt's appointment.
  • Pratt will serve as Managing Director.
  • He joined QIAGEN as CEO on September 1, 2026.

Full Press Release Details

VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that shareholders overwhelmingly approved the appointment of Jonathan M. Pratt as a Managing Director and member of the QIAGEN Managing Board at an Extraordinary General Meeting of Shareholders. Jon Pratt joined QIAGEN as Chief Executive Officer on September 1, 2026. Following today’s shareholder approval, he joins Roland Sackers, Chief Financial Officer, on QIAGEN’s Managing Board. Shar

Frequently Asked Questions

Who is Jonathan M. Pratt?

Jonathan M. Pratt is the newly appointed Managing Director at QIAGEN.

When did Pratt become CEO of QIAGEN?

He became CEO on September 1, 2026.

What was approved at the Extraordinary General Meeting?

Shareholders approved Pratt's appointment as Managing Director.

Who else is on the QIAGEN Managing Board?

Roland Sackers, the Chief Financial Officer, is also on the board.

ShareAdd on Google
Tags: QGEN QIAGEN Jonathan M. Pratt Managing Director shareholders CEO
Last updated: Nov 6, 2026